Formulation and stability testing of itraconazole crystalline nanoparticles

AAPS PharmSciTech

Volumn 12, Issue 3, 2011, Pages 811-820

  Badawi, Alia A ^a   El Nabarawi, Mohamed Ahmed ^a   El Setouhy, Doaa Ahmed ^a   Alsammit, Sami Ahmed ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

itraconazole; nanocrystals; nanoparticles; stability study

Indexed keywords

AEROSIL; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; ITRACONAZOLE; NANOCRYSTAL; POLOXAMER; SOLVENT;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FOURIER TRANSFORM MASS SPECTROMETRY; FREEZE DRYING; HUMIDITY; PRECIPITATION; PRIORITY JOURNAL;

CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DESICCATION; DRUG COMPOUNDING; DRUG STABILITY; FREEZE DRYING; ITRACONAZOLE; NANOPARTICLES; POLOXAMER; POLYSACCHARIDES; SILICON DIOXIDE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 80052591991     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9651-9     Document Type: Article

References (22)

1. A Fasano 1998 Innovative strategies for the oral delivery of drugs and peptides Trends Biotechnol 4 152 157 10.1016/S0167-7799(97)01170-0 (Pubitemid 28172663)
2. CA Lipinski 2002 Poor aqueous solubility-an industry wide problem in drug discovery Am Pharm Rev 5 82 85
3. BE Rabinow 2004 Nanosuspensions in drug delivery Nat Rev Drug Discov 3 9 785 796 15340388 10.1038/nrd1494 1:CAS:528:DC%2BD2cXntFCns7o%3D (Pubitemid 39242830)
4. H Chen C Khemtong X Yang X Chang J Gao 2011 Nanonization strategies for poorly water-soluble drugs Drug Discov Today 16 7-8 354 360 20206289 10.1016/j.drudis.2010.02.009 1:CAS:528:DC%2BC3MXksFemtr8%3D
5. E Merisko-Liversidge GG Liversidge ER Cooper 2003 Nanosizing: a formulation approach for poorly-water-soluble compounds Eur J Pharm Sci 18 2 113 120 12594003 10.1016/S0928-0987(02)00251-8 1:CAS:528:DC%2BD3sXht1Kltrg%3D (Pubitemid 36184748)
6. MV Chaubal C Popescu 2008 Conversion of nanosuspensions into dry powders by spray drying: a case study Pharm Res 25 10 2302 2308 18509597 10.1007/s11095-008-9625-0 1:CAS:528:DC%2BD1cXhtFOru77J
7. CM Buchanan NL Buchanan KJ Edgar S Klein JL Little MG Ramsey, et al. 2007 Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations J Pharm Sci 96 11 3100 3116 17712849 10.1002/jps.20878 1:CAS:528:DC%2BD2sXht12jtrrL (Pubitemid 350221205)
8. W Yang J Tam DA Miller J Zhou JT McConville KP Johnston, et al. 2008 High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers Int J Pharm 361 177 188 18556158 10.1016/j.ijpharm. 2008.05.003 1:CAS:528:DC%2BD1cXpt1alsr8%3D
9. GL Amidon H Lennernäs VP Shah JR Crison 1995 A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res 12 413 420 7617530 10.1023/A:1016212804288 1:CAS:528:DyaK2MXksVGqur8%3D
10. JY Zhang ZG Shen J Zhong TT Hu JF Chen ZQ Ma, et al. 2006 Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants Int J Pharm 323 1-2 153 160 16828244 1:CAS:528: DC%2BD28XpvVOmsLk%3D (Pubitemid 44397363)
11. RS Dhumal SV Biradar S Yamamura AR Paradkar P York 2008 Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability Eur J Pharm Biopharm 70 1 109 115 18502628 10.1016/j.ejpb.2008.04.001 1:CAS:528:DC%2BD1cXhtVOitrvK
12. CM Keck RH Muller 2006 Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization Eur J Pharm Biopharm 62 3 16 16129588 10.1016/j.ejpb.2005.05.009 1:CAS:528:DC%2BD2MXht1Ontb7E (Pubitemid 41736019)
13. G Verreck K Six G Van den Mooter L Baert J Peeters ME Brewster 2003 Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-part I Int J Pharm 251 1-2 165 174 12527186 10.1016/S0378-5173(02)00591-4 1:CAS:528: DC%2BD3sXis1WgtA%3D%3D (Pubitemid 36071471)
14. P Sinswat X Gao MJ Yacaman RO Williams 3rd KP Johnston 2005 Stabilizer choice for rapid dissolving high potency itraconazole particles formed by evaporative precipitation into aqueous solution Int J Pharm 302 1-2 113 124 16109466 10.1016/j.ijpharm.2005.06.027 1:CAS:528:DC%2BD2MXpvVWjtbY%3D (Pubitemid 41242757)
15. B Van Eerdenbrugh L Froyen J Van Humbeeck JA Martens P Augustijns G Van Den Mooter 2008 Alternative matrix formers for nanosuspension solidification: dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion Eur J Pharm Sci 35 4 344 353 18765282 10.1016/j.ejps.2008.08.003
16. B Wang W Zhang W Zhang AS Mujumdar L Huang 2005 Progress in drying technology for nanomaterials Drying Technol 23 7 23 10.1081/DRT-200047900 (Pubitemid 40390262)
17. Y Dong WK Ng S Shen S Kim RB Tan 2009 Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation Int J Pharm 375 1-2 84 88 19481693 10.1016/j.ijpharm.2009.03.013 1:CAS:528:DC%2BD1MXmsFKntbw%3D
18. B Van Eerdenbrugh S Vercruysse JA Martens J Vermant L Froyen J Van Humbeeck, et al. 2008 Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions-a case study with itraconazole Eur J Pharm Biopharm 70 2 590 596 18602992 10.1016/j.ejpb.2008.06.007
19. CL Jackson GB McKenna 1990 The melting behavior of organic materials confined in porous solids J Chem Phys 93 12 9002 9011 10.1063/1.459240 1:CAS:528:DyaK3MXmvFOksg%3D%3D
20. J Lee 2003 Drug nano- and microparticles processed into solid dosage forms: physical properties J Pharm Sci 92 10 2057 2068 14502544 10.1002/jps.10471 1:CAS:528:DC%2BD3sXnvFOms7g%3D (Pubitemid 37175635)
21. B Van Eerdenbrugh L Froyen J Van Humbeeck JA Martens P Augustijns G Van den Mooter 2008 Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion Eur J Pharm Sci 35 1-2 127 135 18644441 10.1016/j.ejps.2008.06.009
22. C Jacobs O Kayser RH Müller 2000 Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide Int J Pharm 196 2 161 164 10699709 10.1016/S0378-5173(99)00412-3 1:CAS:528:DC%2BD3cXhtl2qt78%3D (Pubitemid 30105734)